QR-421a
Phase 1/2Completed 0 views this week 0 watching💤 Quiet
Interest: 22/100
22
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Retinitis Pigmentosa
Conditions
Retinitis Pigmentosa, Usher Syndrome Type 2, Deaf Blind, Retinal Disease, Eye Diseases, Eye Diseases, Hereditary, Eye Disorders Congenital, Vision Disorders
Trial Timeline
Mar 6, 2019 → Oct 14, 2021
NCT ID
NCT03780257About QR-421a
QR-421a is a phase 1/2 stage product being developed by ProQR for Retinitis Pigmentosa. The current trial status is completed. This product is registered under clinical trial identifier NCT03780257. Target conditions include Retinitis Pigmentosa, Usher Syndrome Type 2, Deaf Blind.
What happened to similar drugs?
0 of 3 similar drugs in Retinitis Pigmentosa were approved
Approved (0) Terminated (0) Active (3)
Hype Score Breakdown
Clinical
9
Activity
8
Company
5
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03780257 | Phase 1/2 | Completed |
Competing Products
20 competing products in Retinitis Pigmentosa
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| DSP-3077 Retinal Sheet Cohort 1 + DSP-3077 Retinal Sheet Cohort 2 + DSP-3077 Retinal Sheet Cohort 3 | Sumitomo Pharma | Phase 1/2 | 39 |
| AGN-151597 | AbbVie | Phase 1/2 | 32 |
| CPK850 | Novartis | Phase 1/2 | 36 |
| Valganciclovir + Ganciclovir | Roche | Phase 3 | 40 |
| Valganciclovir | Roche | Pre-clinical | 26 |
| Foscarnet sodium + Ganciclovir | Roche | Phase 1 | 29 |
| Ganciclovir | Roche | Phase 1 | 29 |
| Ganciclovir | Roche | Pre-clinical | 26 |
| Ganciclovir | Roche | Phase 2 | 35 |
| Ganciclovir | Roche | Pre-clinical | 26 |
| Ganciclovir | Roche | Pre-clinical | 26 |
| Zidovudine + Sargramostim + Ganciclovir | Roche | Pre-clinical | 26 |
| Zidovudine + Ganciclovir | Roche | Pre-clinical | 26 |
| Ganciclovir | Roche | Pre-clinical | 26 |
| Interferon beta-1b + Ganciclovir | Roche | Pre-clinical | 26 |
| Ganciclovir | Roche | Pre-clinical | 26 |
| Ganciclovir | Roche | Pre-clinical | 26 |
| Ganciclovir | Roche | Phase 3 | 40 |
| Valganciclovir | Roche | Phase 3 | 36 |
| Cidofovir + Probenecid | Gilead Sciences | Pre-clinical | 26 |